Leerink Not Surprised by CEO Change at Endo Int'l (ENDP); Affirms at 'Market Perform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Oppenheimer Remains Sidelined Following Endo Int'l's (ENDP) New CEO Appointment
September 26, 2016 10:04 AM EDTOppenheimer reiterated a Perform rating on Endo International plc (NASDAQ: ENDP), following the company's announced appointment of Paul Campanelli to president and chief executive officer. Mr. Campanelli joined ENDP in 2015 through the acquisition of Par Pharmaceuticals and most recently served as the CEO of Par. Mr. Campanelli's... More
Piper Jaffray Reiterates Neutral as Endo Int'l (ENDP) Announces Paul Campanelli as New CEO
September 26, 2016 8:26 AM EDTPiper Jaffray reiterated a Neutral rating and $19.00 price target on Endo International plc (NASDAQ: ENDP) following the company's announcement appointment of Paul Campanelli as CEO effective immediately. Mr. Campanelli was responsible for the 2014 acquisition of JHP Pharma, which gave Par a sizable generic injectibles business and more importantly gave the... More
Janney Montgomery Scott Upgrades BioDelivery Sciences International (BDSI) to Buy
September 23, 2016 7:25 AM EDTJanney Montgomery Scott upgraded BioDelivery Sciences International (NASDAQ: BDSI) from Neutral to Buy with a price target of $4.00 as Belbuca will be added as the preferred brand over Butrant on United Healthcare Formulary.
Analyst Ken Trbovich commented, "Endo International plc (NASDAQ:... More
Endo Int'l (ENDP) CEO De Silva Resigns; New CEO Appointed; Guidance Reaffirmed
September 23, 2016 7:03 AM EDTEndo International plc (Nasdaq: ENDP) announced that its Board of Directors has named Paul V. Campanelli President and Chief Executive Officer, effective immediately. Mr. Campanelli currently serves as President of Endo's Generic and OTC drugs business, Par Pharmaceutical, which accounts for approximately 60 percent of Endo's total revenues through the first half of 2016. Campanelli, who will also join Endo's Board of Directors, succeeds Rajiv De Silva, who has stepped down as President, CEO and a member of the Board.
Campanelli, 54, joined Endo in 2015 following Endo's acquisition of Par Pharmaceutical, where he had served as... More
